These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

304 related items for PubMed ID: 21947099

  • 1. [Pharmacoeconomic assessment of daptomycin as first-line therapy for bacteraemia and complicated skin and skin structure infections caused by gram-positive pathogens in Spain].
    Grau S, Rebollo P, Cuervo J, Gil-Parrado S.
    Rev Esp Quimioter; 2011 Sep; 24(3):154-63. PubMed ID: 21947099
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Vancomycin-resistant enterococcal bacteraemia: is daptomycin as effective as linezolid?
    Mave V, Garcia-Diaz J, Islam T, Hasbun R.
    J Antimicrob Chemother; 2009 Jul; 64(1):175-80. PubMed ID: 19423543
    [Abstract] [Full Text] [Related]

  • 5. [Pharmacoeconomic analysis of the treatment of methicillin-resistant Staphylococcus aureus with daptomycin or vancomycin].
    Rubio-Terrés C, Rubio-Rodríguez D, Majos N, Grau S.
    Rev Esp Quimioter; 2012 Dec; 25(4):283-92. PubMed ID: 23303261
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Comparative cost-effectiveness of alternative empiric antimicrobial treatment options for suspected enterococcal bacteremia.
    McComb MN, Collins CD.
    Pharmacotherapy; 2014 Jun; 34(6):537-44. PubMed ID: 24390863
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of linezolid versus vancomycin for hospitalized patients with complicated skin and soft-tissue infections in France.
    De Cock E, Sorensen S, Levrat F, Besnier JM, Dupon M, Guery B, Duttagupta S.
    Med Mal Infect; 2009 May; 39(5):330-40. PubMed ID: 19304423
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Vancomycin-resistant enterococcal bacteraemia and daptomycin: are higher doses necessary?
    King EA, McCoy D, Desai S, Nyirenda T, Bicking K.
    J Antimicrob Chemother; 2011 Sep; 66(9):2112-8. PubMed ID: 21697178
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of the treatment of methicillin-resistant Staphylococcus aureus bacteremia.
    Usery JB, Vo NH, Finch CK, Cleveland KO, Gelfand MS, Self TH.
    Am J Med Sci; 2015 Jan; 349(1):36-41. PubMed ID: 25233042
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effectiveness and safety of daptomycin in complicated skin and soft-tissue infections and bacteraemia in clinical practice: results of a large non-interventional study.
    Gonzalez-Ruiz A, Beiras-Fernandez A, Lehmkuhl H, Dohmen PM, Loeffler J, Chaves RL.
    Int J Antimicrob Agents; 2013 Apr; 41(4):372-8. PubMed ID: 23499225
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study.
    Wilcox MH, Tack KJ, Bouza E, Herr DL, Ruf BR, Ijzerman MM, Croos-Dabrera RV, Kunkel MJ, Knirsch C.
    Clin Infect Dis; 2009 Jan 15; 48(2):203-12. PubMed ID: 19072714
    [Abstract] [Full Text] [Related]

  • 17. Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin Outcomes Registry and Experience (CORE).
    Mohr JF, Friedrich LV, Yankelev S, Lamp KC.
    Int J Antimicrob Agents; 2009 Jun 15; 33(6):543-8. PubMed ID: 19201165
    [Abstract] [Full Text] [Related]

  • 18. Safety and clinical outcomes when utilizing high-dose (> or =8 mg/kg) daptomycin therapy.
    Moise PA, Hershberger E, Amodio-Groton MI, Lamp KC.
    Ann Pharmacother; 2009 Jul 15; 43(7):1211-9. PubMed ID: 19584384
    [Abstract] [Full Text] [Related]

  • 19. Linezolid versus vancomycin for the treatment of gram-positive bacterial infections: meta-analysis of randomised controlled trials.
    Beibei L, Yun C, Mengli C, Nan B, Xuhong Y, Rui W.
    Int J Antimicrob Agents; 2010 Jan 15; 35(1):3-12. PubMed ID: 19900794
    [Abstract] [Full Text] [Related]

  • 20. High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study.
    Kullar R, Davis SL, Levine DP, Zhao JJ, Crank CW, Segreti J, Sakoulas G, Cosgrove SE, Rybak MJ.
    Pharmacotherapy; 2011 Jun 15; 31(6):527-36. PubMed ID: 21923436
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.